RecruitingPhase 1Phase 2NCT07464132

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

Sponsor

Peking Union Medical College Hospital

Enrollment

30 participants

Start Date

Dec 17, 2025

Study Type

INTERVENTIONAL

Conditions

Tumor Cardiovascular Diseases Pulmonary Fibrosis Rheumatic Immune Diseases Involving Large Blood Vessels Hypertrophic Cardiomyopathy (HCM)Other Hypoxic and Fibroblast Activated Diseases

Summary

The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria5

: 18-85 years old
: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis
: Ability to understand and sign informed consent forms
: Expected survival period exceeding 6 months and able to receive follow-up
: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc

Exclusion Criteria5

: Pregnant or lactating women
: Patients allergic to research drug ingredients
: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol/L)
: Patients who participate in other clinical trials and interfere with the results of this study
: Patients with severe illness who cannot cooperate with the examination

Interventions

DRUGInjection of 68Ga-NI-FAPI

Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight

Locations(1)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07464132

Related Trials

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT0407530518 locations

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

NCT035355451 location